乌帕替尼治疗慢性瘙痒性苔藓：病例系列 - Suppr

Suppr

超能文献

Treatment of chronic prurigo with upadacitinib: A case series.

作者信息

Gil-Lianes J, Morgado-Carrasco D, Riquelme-Mc Loughlin C

机构信息

Dermatology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Dermatology Department, Hospital de Figueres, Figueres, Spain.

出版信息

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e106-e109. doi: 10.1111/jdv.19462. Epub 2023 Aug 29.

DOI:10.1111/jdv.19462

PMID:37611279

Abstract

摘要

相似文献

Treatment of chronic prurigo with upadacitinib: A case series.

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e106-e109. doi: 10.1111/jdv.19462. Epub 2023 Aug 29.

Upadacitinib for moderate to severe atopic dermatitis with generalized prurigo nodularis.

Asian J Surg. 2024 Jul;47(7):3084-3088. doi: 10.1016/j.asjsur.2024.02.127. Epub 2024 Mar 6.

A Case of Prurigo Nodularis Associated With Crohn's Disease Responding to Upadacitinib.

Dermatitis. 2024 Sep-Oct;35(5):535-537. doi: 10.1089/derm.2023.0331. Epub 2024 Jan 9.

Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review.

Acta Derm Venereol. 2019 Sep 1;99(10):905-906. doi: 10.2340/00015555-3243.

Update on Chronic Prurigo.

Actas Dermosifiliogr. 2022 Jun;113(6):563-574. doi: 10.1016/j.ad.2021.11.002. Epub 2021 Nov 16.

Use of lenalidomide in treating refractory prurigo nodularis.

J Drugs Dermatol. 2013 Mar;12(3):360-1.

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series.

J Dermatolog Treat. 2023 Dec;34(1):2183729. doi: 10.1080/09546634.2023.2183729.

Upadacitinib for Treatment of Granulomatous Cheilitis.

JAMA Dermatol. 2024 Sep 1;160(9):1001-1003. doi: 10.1001/jamadermatol.2024.2378.

Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

J Am Acad Dermatol. 2024 Nov;91(5):e147-e150. doi: 10.1016/j.jaad.2024.06.094. Epub 2024 Jul 23.

[Efficacy of tracrolimus 0.1% ointment in prurigo].

J Dtsch Dermatol Ges. 2005 Sep;3(9):690-4. doi: 10.1111/j.1610-0387.2005.05740.x.

引用本文的文献

Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.

Allergy Asthma Immunol Res. 2024 Sep;16(5):546-554. doi: 10.4168/aair.2024.16.5.546.

A potential new treatment with upadacitinib for acquired reactive perforating collagenosis.

JAAD Case Rep. 2024 Apr 20;48:112-114. doi: 10.1016/j.jdcr.2024.04.017. eCollection 2024 Jun.

Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.

Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.

Molecular mechanisms of pruritus in prurigo nodularis.

Front Immunol. 2023 Nov 23;14:1301817. doi: 10.3389/fimmu.2023.1301817. eCollection 2023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Treatment of chronic prurigo with upadacitinib: A case series.

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e106-e109. doi: 10.1111/jdv.19462. Epub 2023 Aug 29.

Upadacitinib for moderate to severe atopic dermatitis with generalized prurigo nodularis.

Asian J Surg. 2024 Jul;47(7):3084-3088. doi: 10.1016/j.asjsur.2024.02.127. Epub 2024 Mar 6.

A Case of Prurigo Nodularis Associated With Crohn's Disease Responding to Upadacitinib.

Dermatitis. 2024 Sep-Oct;35(5):535-537. doi: 10.1089/derm.2023.0331. Epub 2024 Jan 9.

Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review.

Acta Derm Venereol. 2019 Sep 1;99(10):905-906. doi: 10.2340/00015555-3243.

Update on Chronic Prurigo.

Actas Dermosifiliogr. 2022 Jun;113(6):563-574. doi: 10.1016/j.ad.2021.11.002. Epub 2021 Nov 16.

Use of lenalidomide in treating refractory prurigo nodularis.

J Drugs Dermatol. 2013 Mar;12(3):360-1.

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series.

J Dermatolog Treat. 2023 Dec;34(1):2183729. doi: 10.1080/09546634.2023.2183729.

Upadacitinib for Treatment of Granulomatous Cheilitis.

JAMA Dermatol. 2024 Sep 1;160(9):1001-1003. doi: 10.1001/jamadermatol.2024.2378.

Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

J Am Acad Dermatol. 2024 Nov;91(5):e147-e150. doi: 10.1016/j.jaad.2024.06.094. Epub 2024 Jul 23.

[Efficacy of tracrolimus 0.1% ointment in prurigo].

J Dtsch Dermatol Ges. 2005 Sep;3(9):690-4. doi: 10.1111/j.1610-0387.2005.05740.x.

引用本文的文献

Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.

Allergy Asthma Immunol Res. 2024 Sep;16(5):546-554. doi: 10.4168/aair.2024.16.5.546.

A potential new treatment with upadacitinib for acquired reactive perforating collagenosis.

JAAD Case Rep. 2024 Apr 20;48:112-114. doi: 10.1016/j.jdcr.2024.04.017. eCollection 2024 Jun.

Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.

Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.

Molecular mechanisms of pruritus in prurigo nodularis.

Front Immunol. 2023 Nov 23;14:1301817. doi: 10.3389/fimmu.2023.1301817. eCollection 2023.